Viracta Total Current Assets from 2010 to 2024

VIRX Stock  USD 0.16  0.01  6.67%   
Viracta Therapeutics Total Current Assets yearly trend continues to be fairly stable with very little volatility. Total Current Assets will likely drop to about 52.9 M in 2024. Total Current Assets is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. View All Fundamentals
 
Total Current Assets  
First Reported
2005-09-30
Previous Quarter
31.1 M
Current Value
21.8 M
Quarterly Volatility
6.5 B
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Viracta Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viracta Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 324.1 K, Interest Expense of 3.9 M or Selling General Administrative of 13.7 M, as well as many indicators such as Price To Sales Ratio of 5.9, Dividend Yield of 0.0 or PTB Ratio of 1.14. Viracta financial statements analysis is a perfect complement when working with Viracta Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Viracta Therapeutics Correlation against competitors.
For more information on how to buy Viracta Stock please use our How to Invest in Viracta Therapeutics guide.

Latest Viracta Therapeutics' Total Current Assets Growth Pattern

Below is the plot of the Total Current Assets of Viracta Therapeutics over the last few years. It is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. Viracta Therapeutics' Total Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Viracta Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Current Assets10 Years Trend
Pretty Stable
   Total Current Assets   
       Timeline  

Viracta Total Current Assets Regression Statistics

Arithmetic Mean52,162,359
Geometric Mean47,692,942
Coefficient Of Variation43.93
Mean Deviation15,865,049
Median46,988,000
Standard Deviation22,917,083
Sample Variance525.2T
Range90.1M
R-Value0.28
Mean Square Error522.5T
R-Squared0.08
Significance0.32
Slope1,414,245
Total Sum of Squares7352.7T

Viracta Total Current Assets History

202452.9 M
202355 M
202293.7 M
2021105.3 M
202047.2 M
201936.3 M
201815.2 M

About Viracta Therapeutics Financial Statements

Viracta Therapeutics investors use historical fundamental indicators, such as Viracta Therapeutics' Total Current Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Viracta Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Current Assets55 M52.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Viracta Stock Analysis

When running Viracta Therapeutics' price analysis, check to measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.